Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 692 results for innovative

  1. OxyMask for delivering oxygen therapy (MIB160)

    NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .

  2. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

  3. Coban 2 for venous leg ulcers (MIB140)

    NICE has developed a medtech innovation briefing (MIB) on Coban 2 for venous leg ulcers .

  4. Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)

    Evidence-based recommendations on selpercatinib (Retsevmo) for untreated RET fusion-positive advanced non-small-cell lung cancer in adults.

  5. Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

    Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.

  6. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

  7. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

  8. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

  9. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)

    Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  10. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB315)

    NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .

  11. SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)

    NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .

  12. Airglove air warming system for venous access (MIB151)

    NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .

  13. pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)

    NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .

  14. Board

    Our board sets out our strategic priorities and policies.

  15. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.